Biogen Idec (NASDAQ:BIIB)

research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
Stock Split Image

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are ...
Read Full Story »
DNA

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund (ETF) has pulled back almost 17% since the February 25 peak, in a sell-off likened to the August 2011 debacle. Trading ...
Read Full Story »
SupremeCourt

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent that would protect ...
Read Full Story »
Morgan Stanley logo

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Like many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Apple, BlackBerry, Chesapeake, Citigroup, King Digital and More

Stocks have recovered from recent woes, but many investors remain fearful of the next sell-off. 24/7 Wall St. reviews many analyst calls each morning, with an eye for new ideas ...
Read Full Story »
West side view of the United States Capitol building.

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the ...
Read Full Story »
research

Catalysts That Could Push Top Biotech Stocks Even Higher

Despite the hard sell-off in the top biotech names last week, most Wall Street firms remain very positive on the leading stocks. The best thing about the carnage inflicted last ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Biogen, Exxon, MarkWest, Yum! and More

Stocks are again challenging news high, and earnings season has all but ended. Investors still worry about buying the top and about the next major market correction. 24/7 Wall St. ...
Read Full Story »
health care

Merrill Lynch’s Top Health Care Stocks to Buy Now

Very quietly, while momentum stocks zoom up and down, one sector has made an almost stealth like move and is leading the S&P 500 so far this year. With the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Return to Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After largely shying away in the previous period, short sellers returned to many of these ...
Read Full Story »
Pills

Biogen Idec Chairman: New Boss Same as the Old Boss?

Biogen Idec Inc. (NASDAQ: BIIB) has announced that Chairman William D. Young will retire from the its board of directors as of the company's 2014 annual meeting of stockholders. Young ...
Read Full Story »
Bull and Bear

Jefferies Says Buy Any Pullback on Top Focus Stocks for Big Gains

The drastic pullback in the S&P 500 has the usual people starting to warn about a market crash, or an emerging market meltdown. Noted bear Bill Fleckenstein said to look ...
Read Full Story »
DNA

Why Caution Is Prevailing in Biotechs Into and After Earnings

Biotechnology stocks struggled on Wednesday after Biogen Idec Inc. (NASDAQ: BIIB) surprised investors with weaker-than-expected guidance for 2014 earnings. The struggles also may be due to simple profit-taking. Stocks in ...
Read Full Story »